Genomics of Alzheimer disease: A review

JAMA Neurology

Volumn 73, Issue 7, 2016, Pages 867-874

  Rosenberg, Roger N ^a,b   Lambracht Washington, Doris ^a   Yu, Gang ^a   Xia, Weiming ^c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b JAMA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE; CD2 ASSOCIATED PROTEIN; CD33 ANTIGEN; CD4 ANTIGEN; EPHRIN RECEPTOR A1; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; PRESENILIN 1; PRESENILIN 2; PSEN1 PROTEIN, HUMAN; PSEN2 PROTEIN, HUMAN;

ABC7 GENE; ALZHEIMER DISEASE; APOLIPOPROTEIN E EPSILON4 GENE; APOLIPOPROTEIN E GENE; APP GENE; BIN1 GENE; CAUSAL ATTRIBUTION; CD2AP GENE; CD33 GENE; CLU GENE; EPHA1 GENE; GENE; GENE MUTATION; GENETIC RISK; GENETIC VARIATION; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MS4A4E GENE; MS4A6A GENE; NONHUMAN; PEDIGREE ANALYSIS; PICALM GENE; PRIORITY JOURNAL; PROTEIN METABOLISM; REGULATORY T LYMPHOCYTE; REVIEW; UPREGULATION; ANIMAL; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; PRESENILIN-2;

EID: 84978114167     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.0301     Document Type: Review

References (119)

1. Selkoe DJ; American College of Physicians; American Physiological Society. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004;140(8):627-638.
2. Haass C, Schlossmacher MG, Hung AY, et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359 (6393):322-325.
3. ShojiM, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992;258(5079): 126-129.
4. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993;32(18):4693-4697.
5. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44(1):181-193.
6. XiaW, Zhang J, Kholodenko D, et al. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem. 1997;272(12):7977-7982.
7. XiaW, Yang T, Shankar G, et al. A specific enzyme-linked immunosorbent assay for measuring beta-Amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66(2): 190-199.
8. HuttonM. Molecular genetics of chromosome 17 tauopathies. Ann N Y Acad Sci. 2000;920:63-73.
9. Lee VM, Trojanowski JQ. Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. J Alzheimers Dis. 2006;9(3)(suppl):257-262.
10. Lewis J,McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy, and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25 (4):402-405.
11. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293(5534):1491-1495.
12. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580): 353-356.
13. CitronM, Oltersdorf T, Haass C, et al. Mutation of the beta-Amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992;360(6405):672-674.
14. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96-99.
15. Das U,Wang L, Ganguly A, et al. Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. Nat Neurosci. 2016;19(1):55-64.
16. Wolfe MS, XiaW, Ostaszewski BL, Diehl TS, KimberlyWT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398(6727):513-517.
17. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearingmissense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375 (6534):754-760.
18. Francis R,McGrath G, Zhang J, et al. aph-1 And pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell. 2002;3 (1):85-97.
19. Yu G, NishimuraM, Arawaka S, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 2000;407(6800):48-54.
20. Ahn K, Shelton CC, Tian Y, et al. Activation and intrinsic gamma-secretase activity of presenilin Proc Natl Acad Sci U S A. 2010;107(50):21435-21440.
21. Lessard CB,Wagner SL, Koo EH. And four equals one: presenilin takes the gamma-secretase role by itself. Proc Natl Acad Sci U S A. 2010;107(50): 21236-21237.
22. Li YM, Xu M, Lai MT, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin Nature. 2000;405 (6787):689-694.
23. Shah S, Lee SF, Tabuchi K, et al. Nicastrin functions as a gamma-secretase-substrate receptor. Cell. 2005;122(3):435-447.
24. CitronM,Westaway D, XiaW, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 1997;3(1):67-72.
25. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2(8):864-870.
26. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38(1):24-26.
27. Wisniewski KE,Wisniewski HM,Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985;17(3):278-282.
28. Haass C, Lemere CA, Capell A, et al. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med. 1995;1(12): 1291-1296.
29. Nilsberth C,Westlind-Danielsson A, Eckman CB, et al. The "Arctic" APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4 (9):887-893.
30. Goate A, Chartier-Harlin M-C, MullanM, et al. Segregation of amissense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349(6311):704-706.
31. Murrell JR, Hake AM, Quaid KA, FarlowMR, Ghetti B. Early-onset Alzheimer disease caused by a new mutation (V717L) in the amyloid precursor protein gene. Arch Neurol. 2000;57(6):885-887.
32. Murrell J, FarlowM, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 1991;254(5028):97-99.
33. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease [published correction appears in Nat Genet. 2013;45(6):712]. Nat Genet. 2009;41(10):1088-1093.
34. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436-441.
35. Hollingworth P, Harold D, Sims R, et al; Alzheimer's Disease Neuroimaging Initiative; CHARGE consortium; EADI1 consortium. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33, and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429-435.
36. Lambert JC, Heath S, Even G, et al; European Alzheimer's Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094-1099.
37. StrittmatterWJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-Avidity binding to beta-Amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977-1981.
38. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 1993;11(4):575-580.
39. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3 (89):89ra57.
40. Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13(9):1029-1031.
41. Deane R,Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43(3): 333-344.
42. Zlokovic BV, Martel CL, Matsubara E, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A. 1996;93(9):4229-4234.
43. Ma J, Yee A, Brewer HB Jr., Das S, Potter H. Amyloid-Associated proteins alpha 1-Antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372(6501):92-94.
44. DeMattos RB, O'dellMA, Parsadanian M, et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2002; 99(16):10843-10848.
45. Bell RD, Sagare AP, Friedman AE, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007; 27(5):909-918.
46. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857-865.
47. HenekaMT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493 (7434):674-678.
48. Jun G, Naj AC, Beecham GW, et al; Alzheimer's Disease Genetics Consortium. Meta-Analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67(12):1473-1484.
49. Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol. 2013;14(8):812-820.
50. Frenkel D, Wilkinson K, Zhao L, et al. Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer's-like disease progression. Nat Commun. 2013;4(2030):2030.
51. Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153(3):707-720.
52. Guerreiro R,Wojtas A, Bras J, et al; Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2): 117-127.
53. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368(2): 107-116.
54. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78 (4):631-643.
55. Bradshaw EM, Chibnik LB, Keenan BT, et al; Alzheimer Disease Neuroimaging Initiative. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16 (7):848-850.
56. KimWS, Li H, Ruberu K, et al. Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20mouse model of Alzheimer's disease. J Neurosci. 2013;33(10):4387-4394.
57. Satoh K, Abe-Dohmae S, Yokoyama S, St George-Hyslop P, Fraser PE. ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing. J Biol Chem. 2015;290(40):24152-24165.
58. Perez RG, Squazzo SL, Koo EH. Enhanced release of amyloid beta-protein from codon 670/671 "Swedish" mutant beta-Amyloid precursor protein occurs in both secretory and endocytic pathways. J Biol Chem. 1996;271(15):9100-9107.
59. Cirrito JR, Kang JE, Lee J, et al. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58(1):42-51.
60. Chapuis J, Hansmannel F, Gistelinck M, et al; GERAD consortium. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry. 2013;18(11):1225-1234.
61. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168-177.
62. Offe K, Dodson SE, Shoemaker JT, et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci. 2006;26(5):1596-1603.
63. Andersen OM, Reiche J, Schmidt V, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005; 102(38):13461-13466.
64. Haas IG, Frank M, Véron N, Kemler R. Presenilin-dependent processing and nuclear function of gamma-protocadherins. J Biol Chem. 2005;280(10):9313-9319.
65. Georgakopoulos A, Marambaud P, Efthimiopoulos S, et al. Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. Mol Cell. 1999;4(6):893-902.
66. Marambaud P,Wen PH, Dutt A, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell. 2003;114(5):635-645.
67. Blanco P, Sargent CA, Boucher CA,MitchellM, Affara NA. Conservation of PCDHX in mammals; expression of human X/Y genes predominantly in brain. Mamm Genome. 2000;11(10):906-914.
68. Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet. 2009;41(2):192-198.
69. Inoue E, Deguchi-Tawarada M, Togawa A, et al. Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation. J Cell Biol. 2009;185 (3):551-564.
70. Lynch DK, Winata SC, Lyons RJ, et al. A Cortactin-CD2-Associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem. 2003;278(24): 21805-21813.
71. Liao F, Jiang H, Srivatsan S, et al. Effects of CD2-Associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model. Mol Neurodegener. 2015;10:12.
72. MullanM, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-Amyloid. Nat Genet. 1992;1(5):345-347.
73. CitronM, Oltersdorf T, Haass C, et al. Mutation of the beta-Amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 1992;360(6405):672-674.
74. ChenWT, Hong CJ, Lin YT, et al. Amyloid-beta (Aβ) D7H mutation increases oligomeric Aβ42 and alters properties of Aβ-zinc/copper assemblies. PLoS One. 2012;7(4):e35807.
75. Wakutani Y,Watanabe K, Adachi Y, et al. Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75(7): 1039-1042.
76. Zhou L, Brouwers N, Benilova I, et al. Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β'-site increases Aβ generation. EMBO Mol Med. 2011;3(5):291-302.
77. Kaden D, Harmeier A,Weise C, et al. Novel APP/Aβ mutation K16N produces highly toxic heteromeric Aβ oligomers. EMBO Mol Med. 2012;4 (7):647-659.
78. Hendriks L, van Duijn CM, Cras P, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-Amyloid precursor protein gene. Nat Genet. 1992;1(3):218-221.
79. Kamino K, Orr HT, Payami H, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet. 1992;51(5):998-1014.
80. Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990;248(4959):1124-1126.
81. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol. 2001;49(6):697-705.
82. Kumar-Singh S, De Jonghe C, CrutsM, et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum Mol Genet. 2000;9(18): 2589-2598.
83. Cruts M, Dermaut B, Rademakers R, Van den Broeck M, Stögbauer F, Van Broeckhoven C. Novel APP mutation V715A associated with presenile Alzheimer's disease in a German family. J Neurol. 2003;250(11):1374-1375.
84. Ancolio K, Dumanchin C, Barelli H, et al. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715-Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Proc Natl Acad Sci U S A. 1999;96(7):4119-4124.
85. Eckman CB, Mehta ND, Crook R, et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet. 1997;6(12):2087-2089.
86. Guerreiro RJ, BaqueroM, Blesa R, et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging. 2010;31(5): 725-731.
87. Kwok JB, Li QX, Hallupp M, et al. Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis. Ann Neurol. 2000;47(2):249-253.
88. Theuns J, Marjaux E, VandenbulckeM, et al. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum Mutat. 2006;27(9):888-896.
89. Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem. 1996; 271(31):18295-18298.
90. Hardy J. New insights into the genetics of Alzheimer's disease. Ann Med. 1996;28(3):255-258.
91. Bateman RJ, Xiong C, Benzinger TL, et al; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9): 795-804.
92. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46-54.
93. Fox NC, Black RS, Gilman S, et al; AN1792(QS-21)-201 Study. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64(9):1563-1572.
94. Salloway S, Sperling R, Gilman S, et al; Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061-2070.
95. Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-β-Amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci. 2012;32(28):9677-9689.
96. Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis. 2012;28(1):49-69.
97. FarlowM, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012; 8(4):261-271.
98. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009; 30(11):1728-1736.
99. Gilman S, KollerM, Black RS, et al; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9): 1553-1562.
100. Blennow K, Zetterberg H, Rinne JO, et al; AAB-001 201/202 Investigators. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69(8):1002-1010.
101. Miller G. Alzheimer's research: stopping Alzheimer's before it starts. Science. 2012;337 (6096):790-792.
102. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012;2(10):975-984.
103. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(suppl 3): 321-329.
104. Lambracht-Washington D, Rosenberg RN. DNA Aβ42 immunization generates a multivalent vaccine: antibodies in plasma of active full-length DNA Aβ42 immunizedmice show polyclonal Aβ42 peptide binding. Paper presented at: Alzheimer's Association International Conference; 2015; Washington, DC.
105. Vasilevko V, Pop V, Kim HJ, et al. Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis. 2010;39(3):301-310.
106. Hatami A, Albay R III, Monjazeb S, Milton S, Glabe C. Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. J Biol Chem. 2014;289(46):32131-32143.
107. Qu BX, Lambracht-Washington D, FuM, Eagar TN, Stüve O, Rosenberg RN. Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine. 2010;28(32):5280-5287.
108. Qu B, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenicmice. J Neurol Sci. 2006;244(1-2):151-158.
109. Qu BX, Xiang Q, Li L, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci. 2007;260(1-2):204-213.
110. Lambracht-Washington D, Rosenberg RN. Anti-Amyloid beta to tau-based immunization: Developments in immunotherapy for Alzheimer disease. Immunotargets Ther. 2013;2013(2):105-114.
111. Lambracht-Washington D, Qu BX, Fu M, et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. J Neuroimmunol. 2013;254(1-2):63-68.
112. Lambracht-Washington D, Qu BX, Fu M, et al. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol. 2011;31 (6):867-874.
113. Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN. DNA beta-Amyloid(1-42) trimer immunization for Alzheimer disease in awild-type mouse model. JAMA. 2009;302(16):1796-1802.
114. Lambracht-Washington D, Rosenberg RN. Advances in the development of vaccines for Alzheimer's disease. Discov Med. 2013;15(84): 319-326.
115. Lambracht-Washington D, Rosenberg RN. Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapy. J Neuroimmunol. 2015;278:90-99.
116. Lambracht-Washington D, Rosenberg RN. A noninflammatory immune response in aged DNA Aβ42-immunizedmice supports its safety for possible use as immunotherapy in AD patients. Neurobiol Aging. 2015;36(3):1274-1281.
117. Rosenberg RN. Defining amyloid pathology in persons with and without dementia syndromes: making the right diagnosis. JAMA. 2015;313(19): 1913-1914.
118. Rosenberg RN, Lambracht-Washington D. DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease. JAMA Neurol. 2013;70(6):772-773.
119. Rosenberg RN, Petersen RC. The Human Alzheimer Disease Project: a new call to arms. JAMA Neurol. 2015;72(6):626-628.